Market Size
The Global Geographic Atrophy (GA) Market reached US$ 22.70 billion in 2025 and is expected to reach US$ 38.80 billion by 2033 growing with a CAGR of 7.2% during the forecast period 2026-2033.
The Geographic Atrophy market is driven by factors such as increasing prevalence of the disease, increasing research and development, rising funding for research, and collaboration among key players.
In Geographic Atrophy, the macula of the retina is impacted by the eye ailment macular degeneration. The center of vision is severely impaired by this condition. The peripheral vision what we can see on the sides of the center will still be available. Geographic atrophy typically affects both eyes (bilaterally). Geographic atrophy causes blind patches (scotoma) in the center of vision as well as partial vision loss in terms of sharpness. There are more than 8 million geographic atrophy sufferers worldwide. About 20% of the population has age-related macular degeneration.
Market Scope
| Metrics | Details |
| CAGR | 7.2% |
| Size Available for Years | 2025-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Treatment Type, Age Group, End Users |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and key Insights. |
For more details on this report – Request for Sample
Market Dynamics and Trends
The Increasing FDA Approval is Driving the Global Geographic Atrophy Market Growth
In August 2023, the FDA authorized IZERVAY (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD) according to a statement from Astellas Pharma Inc. The only licensed GA medication showing a statistically significant decrease (p0.01) in the rate of GA progression at the 12-month primary objective across two Phase 3 clinical trials is IZERVAY, a novel complement C5 inhibitor.
The GATHER1 and GATHER2 Phase 3 clinical trials, which assessed the safety and effectiveness of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD, served as the foundation for the FDA's clearance. In the beginning, six months, and twelve months, the GA growth rate was assessed. The major analysis of each registrational trial over a 12-month period revealed that patients who received IZERVAY as opposed to sham treatment experienced a statistically significant slower rate of GA increase.
The Increasing Collaboration Among Key Players to Research Treatment for Geographic Atrophy Boosts the Global Geographic Atrophy Market Growth
For instance, in February 2023, Rallybio Corporation, a clinical-stage biotechnology company dedicated to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, and EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced a research collaboration.
The collaboration will assess the sustained intraocular medication delivery of Rallybio's inhibitor of complement component 5 (C5) using EyePoint's exclusive Durasert technology. Geographic atrophy, an advanced form of age-related macular degeneration that causes irreversible visual loss, will be the initial focus. They are thrilled to start this research in the hopes of bettering the lives of people suffering from eye illnesses like geographic atrophy because the use of C5 inhibitors for the treatment of eye disease has shown significant potential.
Challenges with Geographic Atrophy are Hampering the Global Geographic Atrophy Market Growth
This can be a serious problem, especially in remote or underdeveloped locations with scarce healthcare resources. Lack of access to eye doctors can make it challenging to identify and treat eye diseases, which could have an impact on people's vision and general quality of life. Uncertainty about eye illnesses can be a serious public health issue.
If left untreated, a variety of eye diseases can result in issues like vision loss. Increasing people's awareness of common eye conditions, their risk factors, and the value of routine eye exams might encourage people to adopt preventative measures and seek treatment as soon as necessary.
Market Segmentation Analysis
The global geographic atrophy market is segmented based on treatment type, age group, end user, and region.
The AREDS2 supplements Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period
The AREDS2 supplements segment accounted for the highest market stake accounting for approximately 45.2% of the geographic atrophy market in 2022.
The National Eye Institute (NEI) in the United States undertook the AREDS2 study (Age-Related Eye Disease Study 2) to test the impact of dietary supplements on the progression of age-related macular degeneration (AMD). One type of AMD is geographic atrophy, commonly referred to as atrophic or dry AMD.
These antioxidant-rich supplements underwent testing as part of the Age-Related Eye Disease Study. These are used by certain medical professionals to treat dry age-related macular degeneration. The same components are included in an AREDS1 formula together with beta-carotene. However, beta-carotene has been linked to lung cancer among smokers. Lutein, zeaxanthin, vitamin E, zinc oxide, and cupric oxide are all components of AREDS2.
The findings of the AREDS2 trial revealed that the modified AREDS2 formulation, which reduced the zinc dose and replaced beta-carotene with lutein and zeaxanthin, was equally as beneficial in lowering the risk of AMD progression as the original AREDS formulation.
Source: DataM Intelligence Analysis (2023)
Market Geographical Share
North America Holds a Dominant Position in the Global Geographic Atrophy Market
North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. In July 2023, Apellis Pharmaceuticals, Inc. reported that Geographic atrophy (GA), a complication of age-related macular degeneration (AMD), was treated in real-world settings with SYFOVRE (pegcetacoplan injection).
These incidents are still extremely uncommon even after 68,000 commercial vials have been delivered and 23,000 clinical trial injections. Additionally, during the course of their ongoing assessment, they found no evidence that problems with the manufacturing or drug product may have led to these incidents. The company will keep working with the retinal community to provide a secure, efficient remedy for geographic atrophy.
Source: DataM Intelligence Analysis (2023)
Market Companies
The major global players in the market include Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals, Inc. (US), Allegro Ophthalmics, LLC (US), Stealth BioTherapeutics (Cayman Islands), Gyroscope Therapeutics Limited (UK), Regenerative Patch Technologies, LLC (US), Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), and NGM Biopharmaceuticals Inc. (US) among others.
Recent Developments
- On March 31, 2026, Biogen Inc. announced the acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, strengthening its position in ophthalmology and rare disease therapies. The deal includes SYFOVRE (pegcetacoplan), the first FDA-approved treatment for geographic atrophy, and is expected to expand global access to GA patients while accelerating Biogen’s growth in retinal disease therapeutics.
- On November 12, 2025, Apellis Pharmaceuticals reported long-term GALE study data showing that SYFOVRE delayed geographic atrophy lesion growth by approximately 1.5 years over five years of continuous treatment. The findings reinforce the therapy’s disease-modifying potential and strengthen its clinical positioning as a leading treatment for GA secondary to age-related macular degeneration.
- On November 15, 2025, Astellas Pharma announced regulatory discussions with the U.S. FDA regarding its GA therapy IZERVAY (avacincaptad pegol), after earlier efforts to expand dosing flexibility and update labeling were not approved. The development highlights continued regulatory scrutiny and competition in the GA treatment landscape, particularly regarding dosing frequency and long-term efficacy claims.
- On June 18, 2025, the geographic atrophy treatment landscape continued to expand as real-world studies and post-marketing surveillance data confirmed increasing adoption of complement inhibitor therapies such as SYFOVRE and IZERVAY across North America and Europe. Market uptake is being driven by rising diagnosis rates and improved awareness of GA progression among ophthalmologists.
- On April 9, 2025, Regeneron Pharmaceuticals and partners continued late-stage development of combination and next-generation retinal therapies targeting complement pathways, aiming to improve efficacy and reduce injection burden for GA patients. These pipeline advancements reflect increasing competition in complement inhibition-based ophthalmology treatments.
- On January 22, 2025, global ophthalmology-focused biotech companies increased investments in retinal imaging, AI-based GA detection, and early intervention programs, enabling earlier diagnosis of geographic atrophy and supporting faster adoption of newly approved therapies in clinical practice.
- On December 2025, industry reports highlighted growing collaboration between pharmaceutical companies and retinal specialty clinics to improve real-world treatment adherence for GA therapies, as frequent intravitreal injections remain a key challenge in long-term disease management.
Why Purchase the Report?
- To visualize the global geographic atrophy market segmentation based on the treatment type, age group, diagnosis, end user, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of geographic atrophy market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of critical products of all the major players.
The global geographic atrophy market report would provide approximately 61 tables, 57 figures, and 195 Pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
